WG
LXRX icon

Winton Group’s Lexicon Pharmaceuticals LXRX Stock Holding History

Winton Group’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
43,200
+17,700
+69% +$34.5K ﹤0.01% 1087
2026
Q1 		$39.8K Buy
+25,500
New +$37.1K ﹤0.01% 1070
2022
Q1 		– Sell
-10,688
Closed -$42K – 1073
2021
Q4 		$42K Sell
10,688
-101,432
-90% -$493K ﹤0.01% 982
2021
Q3 		$539K Sell
112,120
-36,182
-24% -$148K 0.03% 825
2021
Q2 		$681K Sell
148,302
-15,367
-9% -$74K 0.04% 745
2021
Q1 		$961K Sell
163,669
-29,221
-15% -$202K 0.05% 485
2020
Q4 		$660K Sell
192,890
-182,273
-49% -$348K 0.05% 639
2020
Q3 		$540K Buy
375,163
+40,452
+12% +$72K 0.02% 1081
2020
Q2 		$668K Buy
334,711
+169,000
+102% +$331K 0.02% 1119
2020
Q1 		$323K Buy
+165,711
New +$493K 0.01% 1152
2019
Q4 		– Sell
-23,838
Closed -$72K – 1677
2019
Q3 		$72K Buy
+23,838
New +$73.8K ﹤0.01% 1480

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Winton Group's LXRX Position: Q2 2026 in Review

Winton Group increased its Lexicon Pharmaceuticals (LXRX) stake by 69% in Q2 2026, buying an estimated $34.5K and bringing the position to 43,200 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1087.

Winton Group first reported a position in LXRX in Q3 2019 and has held it in 11 quarters since. The position peaked at $961K in Q1 2021. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Winton Group held 43,200 shares of Lexicon Pharmaceuticals worth $104K as of Q2 2026.
  • Winton Group bought 17,700 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $34.5K.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1087 holding.
  • Winton Group first reported a position in Lexicon Pharmaceuticals in Q3 2019 and has held it in 11 quarters since.
  • Winton Group's Lexicon Pharmaceuticals position peaked at $961K in Q1 2021.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.